Acrivon ABAcrivon AB
Acrivon AB

Acrivon AB

Website
2022Active
Advertise here

About

Acrivon AB develops targeted therapies for cancer patients by matching drug mechanisms to the biologic drivers of cancer using their proprietary AP3 platform. This platform uncovers drug sensitivity not achievable through genomics, enabling them to improve patient outcomes with their pipeline programs, including ACR-368, ACR-2316, and ACR-6840. Acrivon also partners with other companies to develop predictive OncoSignature tests for drug candidates.

Technology stack

detected 2026-06-14
Est. monthly stack spend~$360/mo
CDN
Cloudflare
EmailMimecast
gateway-fronted
Stack
ReactWordPress
Analytics
Google Analytics 4
SEO
Yoast SEO
Compliance
GDPRCCPA
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Acrivon AB do?

Acrivon AB develops targeted therapies for cancer patients by matching drug mechanisms to the biologic drivers of cancer using their proprietary AP3 platform. This platform uncovers drug sensitivity not achievable through genomics, enabling them to improve patient outcomes with their pipeline programs, including ACR-368, ACR-2316, and ACR-6840. Acrivon also partners with other companies to develop predictive OncoSignature tests for drug candidates.

How much funding has Acrivon AB raised?

Acrivon AB has raised a total of $10M in funding. The most recent round on record is Seed.

Where is Acrivon AB headquartered?

Acrivon AB is headquartered in Uppsala, Sweden.

When was Acrivon AB founded?

Acrivon AB was founded in 2022.

What industry does Acrivon AB operate in?

Acrivon AB operates in AI Tools & Apps, AI Drug Discovery, Biotech, HealthTech, Foundation Model, Generative AI.